Outlook Therapeutics, Inc. Stockholders Equity

Quick Answer

Outlook Therapeutics, Inc. reported Stockholders Equity of -$32.19 million for fiscal year 2025.

Outlook Therapeutics, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 -$32.19M +56.0%
2024 -$73.08M -406.1%
2023 -$14.44M -265.3%
2022 $8.74M +89.6%
2021 $4.61M +63.0%
2020 $2.83M +117.5%
2019 -$16.13M +36.9%
2018 -$25.54M +24.1%
2017 -$33.65M -550.5%
2016 -$5.17M +90.5%
2015 -$54.22M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
December 31, 2025 -$38.55M +23.3% -19.8%
September 30, 2025 -$32.19M +56.0% +13.5%
June 30, 2025 -$37.19M +55.6% -14.6%
March 31, 2025 -$32.46M +75.8% +35.4%
December 31, 2024 -$50.29M -106.6% +31.2%
September 30, 2024 -$73.08M -406.1% +12.7%
June 30, 2024 -$83.67M -1420.6% +37.7%
March 31, 2024 -$134.24M -1379.9% -451.4%
  • Outlook Therapeutics, Inc. showed an increase of +56.0% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2015–2025 period, Outlook Therapeutics, Inc.’s stockholders equity has grown by 40.6% (from -$54.22 million to -$32.19 million).
  • The most recent figure is from Outlook Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 19, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment